Predictive Value of Renal Venous Flow Profiles for Adverse Outcomes in Right Heart Failure

University of Giessen

Status: Completed

Conditions: Cardiorenal Syndrome; Heart Failure; Pulmonary Hypertension

Treatments: Diagnostic Test: No intervention

Study type: Observational

Funder types: Other

Identifiers

NCT03039959

AZ 237/16

Details and patient eligibility

About

Predictive value of renal venous flow profiles for adverse outcomes in patients with right heart failure

Full description

Persistent congestion with deteriorating renal function is an important cause of adverse outcomes in heart failure. The investigators aimed to characterize new Doppler ultrasonography approaches to evaluate the continuum of renal congestion. Pulmonary hypertension is the most common precursor to right heart failure and thus represents an ideal scenario to study congestion. The second cohort comprises consecutive Cardiology inpatients aged ≥18 years with a new or pre-existing diagnosis of heart failure who are referred to the consultant nephrologist with a history of diuretic-resistant fluid overload and impaired renal function. The investigators choose patients with heart failure to broaden the findings to the most common clinical entity of right ventricular failure.

Enrollment: 421 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Pulmonary hypertension cohort:

Exclusion Criteria:

• CKD stage 5 (KDIGO)
• pre-existing acute kidney injury (acute kidney injury was defined as an increase in serum creatinine by ≥ 0.3 mg/dl within 48 hours or to ≥ 1.5 times baseline within the prior 7 days, as determined by all available serum creatinine values from hospital and outpatient medical records within the previous 90 days)
• Non-end stage renal disease patients with extracorporeal or peritoneal ultrafiltration for treatment of diuretic-resistant fluid overload
• Patients with primary kidney disease (e.g., glomerulonephritis, autosomal dominant polycystic kidney disease, postrenal obstruction)
• solid-organ transplant recipients
• use of non-steroidal inflammatory drugs within 72 hours before right heart catheterization

Heart failure cohort:

Exclusion criteria same as in the discovery cohort except pre-existing acute kidney injury

• Patients with mechanical assist devices are excluded

Trial design

421 participants in 2 patient groups

Pulmonary hypertension cohort

Description:

Consecutive adult Pulmonology inpatients with suspected or pre-diagnosed pulmonary hypertension undergoing invasive right heart catheterization.

Treatment:

Diagnostic Test: No intervention

Heart failure cohort

Description:

Consecutive adult Cardiology inpatients with a new or pre-existing diagnosis of heart failure who are referred to the consultant nephrologist with a history of diuretic-resistant fluid overload and impaired renal function.

Treatment:

Diagnostic Test: No intervention